



Substitute for form 1449/APTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 1 of 2

**Complete if Known**

Application Number	10/712,799
Filing Date	November 12, 2003
First Named Inventor	Ilan KOR
Art Unit	1626
Examiner Name	Rebecca L. Anderson
Attorney Docket Number	1662/53605

**U.S. PATENT DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code <sup>2</sup> (if known)			
	1	5,760,069	06-02-1998	Lukas-Laskey et al.	
	2	5,902,821	05-11-1999	Lukas-Laskey et al.	
	3	6,022,562	02-08-2000	Autant et al.	
	4	6,730,326	05-04-2004	Beyer et al.	
	5	6,777,559	08-17-2004	Scalone et al.	
	6	7,169,935	01-30-2007	Scalone et al.	
	7	2004/0127723	07-01-2004	Scalone et al.	
	8	2004/0198812	10-07-2004	Bubendorf et al.	
	9	2005/0240027	10-27-2005	Brook et al.	
	10	2005/0277689	12-15-2005	Brook et al.	
	11	2006/0148878	07-06-2006	Bubendorf et al.	
	12	2006/0167077	07-27-2006	Hercek et al.	
	13	2006/0270858	11-30-2006	Chhabada et al.	
	14	2007/0027202	02-01-2007	Kumar et al.	
	15	2007/0055069	03-08-2007	Ramanjaneyulu et al.	
	16	2007/0112054	05-17-2007	Knipp et al.	
	17	2007/0191456	08-16-2007	Tarur et al.	
	18	2007/0197797	08-23-2007	Harrington	

**FOREIGN PATENT DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	†
		Country Code <sup>2</sup> - Number <sup>3</sup> - Kind Code <sup>4</sup> (if known)				
	19	WO 01/035938	05-25-2001	Dr. Willmar Schwabe GmbH & Co.		
	20	WO 03/059807	07-27-2003	Teva Pharmaceutical Industries Ltd.		
	21	WO 04/041783	05-21-2004	Zentiva, A.S.		
	22	WO 04/094378	11-04-2004	Matrix Laboratories Ltd.		
	23	WO 05/021504	03-10-2005	KRKA, Tovarna Zdravil, D.D., Novo Mesto		
	24	WO 05/080329	09-01-2005	Cadila Healthcare Limited		
	25	WO 05/113502	12-01-2005	Cipla Limited		
	26	WO 05/115981	12-08-2005	USV Limited		
	27	WO 06/061364	06-15-2006	Zambon Group S.p.A.		
	28	WO 07/077111	07-12-2007	F. Hoffman-La Roche AG		
	29	WO 07/097504	08-30-2007	Ahn-Gook Pharmaceutical Co., Ltd. et al.		

Examiner Signature /Rebecca Anderson/ Date Considered 12/03/2008

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /RA/

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 2 of 2

**Complete if Known**

Application Number	10/712,799
Filing Date	November 12, 2003
First Named Inventor	Ilan KOR
Art Unit	1626
Examiner Name	Rebecca L. Anderson
Attorney Docket Number	1662/53605

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>

Examiner Signature	/Rebecca Anderson/	Date Considered	12/03/2008
-----------------------	--------------------	--------------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /RA/